Register for OBR daily


KH_OMA_300x250

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

PARD $0.34 0.1299 +61.86%
MACK $6.68 0.3100 +4.87%
CLVS $43.66 1.7200 +4.10%
GALT $5.05 0.1920 +3.95%
ADXS $3.27 0.1191 +3.78%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CRIS $1.53 -0.1160 -7.03%
CBMG $17.50 -1.2699 -6.77%
INFI $10.48 -0.4600 -4.20%
FPRX $10.60 -0.4600 -4.16%
SNSS $6.46 -0.2800 -4.15%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | Next > | Last >>

Halaven Fails to Meet Primary Endpoint in NSCLC

(Healio) Aug 8, 2014 - Results from a phase 3 trial have found that eribulin did not meet its primary endpoint of OS for the treatment of non-small cell lung cancer that has progressed following two or more prior treatment regimens, the manufacturer announced today.
read article 



U.S. Lung Cancer Rates Falling Overall, Study Finds

(Philly.com/HealthDay News) Aug 11, 2014 - Overall lung cancer rates are dropping, according to a new analysis of nearly a half million Americans with lung cancer. But, the news wasn't all good -- the study also found that the rates of certain types of lung cancer are increasing, according to researchers from the U.S. National Cancer Institute (NCI).
read article 



FDA Approves J&J Diabetes Drug Invokamet

(PharmaTimes [UK]) Aug 10, 2014 - Regulators in the USA have given the green light to Johnson & Johnson's new diabetes combo Invokamet.
read article 



A Stem Cell Study Shows Promising Results for Severe Stroke Patients

(Washington Post) Aug 11, 2014 - A London study showed marked improvement for five stroke patients treated with stem cells.
read article (free registration required) 



29 States Seek Tighter E-Cigarette Regulations

(New York Times) Aug 8, 2014 - Twenty-nine state attorneys general on Friday urged the Food and Drug Administration to strengthen its proposed regulations on electronic cigarettes, a business that has exploded into a $2.5 billion industry with virtually no regulatory oversight.
read article 



Clinical Trial to Start Soon on GSK Ebola Vaccine

(Reuters) Aug 11, 2014 - A clinical trial of an experimental vaccine against the deadly Ebola virus is set to start shortly, according to British drugmaker GlaxoSmithKline, which is co-developing the product with U.S. scientists.
read article 



Sanofi to Pay MannKind Up to $925m for Inhaled Insulin

(Bloomberg) Aug 11, 2014 - Sanofi agreed to pay MannKind Corp. as much as $925 million for global rights to the world’s only available inhaled insulin less than seven weeks after the drug won regulatory approval in the U.S.
read article 



Faster FDA Approvals Have Not Caused More Drug Safety Problems

(Forbes/The Apothecary blog) Aug 8, 2014 - The media gave some attention to a new study, which suggested that the Food and Drug Administration (FDA) recklessly allows unsafe new prescription drugs onto the market.
read article 



Things You Should Never Say to Someone Who Has Cancer

(Yahoo! Health/Woman's Day) Aug 8, 2014 - According to Barbara L. Andersen, PhD, a researcher and professor of psychology, two of the best things to say are easy: “I’m sorry you’re ill” and “I’m thinking of you.”
read article 



Living With Cancer: Difficult Choices

(New York Times/Well blog) Aug 7, 2014 - A series of problematic choices confront anyone dealing with cancer.
read article 



Equicare Health Announces a Partnership with e+CancerCare

(Yahoo! Finance) Aug 11, 2014 - Equicare to provide integrated software that enables e+ to deliver coordinated Navigation, Survivorship & Patient Portal Services to their centers.
read article 



National Effort to Find New Cancer-fighting Drugs Takes Root at UC Davis

(Sacramento Bee) Aug 9, 2014 - A national lung cancer trial launched earlier this summer with the help of a UC Davis oncologist has the potential to dramatically affect the way cancer drugs will be developed in the future.
read article 



ASCO, AACR Urge FDA to Regulate All Tobacco Products—Including E-cigarettes

(ASCO in Action) Aug 11, 2014 - The American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR), in a joint letter responding to a proposal by the U.S. Food and Drug Administration (FDA) to extend its regulatory authority over tobacco products, urged the agency to regulate electronic cigarettes, cigars, and all other tobacco products and to strengthen the proposed regulations for newly deemed products.
read article 



Colgate Total Ingredient Linked to Hormones, Cancer Spotlights FDA Process

(Bloomberg) Aug 11, 2014 - The chemical triclosan has been linked to cancer-cell growth and disrupted development in animals. Regulators are reviewing whether it’s safe to put in soap, cutting boards and toys. Consumer companies are phasing it out.
read article 



Mylan Launches Generic Xeloda® Tablets

(Mylan) Aug 11, 2014 - Mylan Inc. today announced that it has launched Capecitabine Tablets USP, 150 mg and 500 mg, the generic version of Genentech's Xeloda® Tablets.
read corporate press release 



Mirati Therapeutics Receives Orphan Designation from U.S. Food & Drug Administration for Mocetinostat in Diffuse Large B-Cell Lymphoma

(San Francisco Business Times) Aug 11, 2014 - Mirati Therapeutics, Inc. today announced that the U.S. FDA has granted Orphan Drug Designation to mocetinostat, a spectrum selective HDAC inhibitor, for diffuse large B-cell lymphoma (DLBCL).
read article 



Insurance Status May Affect Cancer Outcome: Study

(U.S. News & World Report/HealthDay News) Aug 8, 2014 - Up to 33 percent of the cancer patients without insurance or with Medicaid died within two years of diagnosis, compared to just 14 percent of those with other kinds of insurance.
read article 



Avillion Announces Dosing of First Patients in Phase 3 BFORE Trial to Assess BOSULIF(R) (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia

(MarketWatch) Aug 11, 2014 - Avillion LLP announces that the first patients have been dosed in the United States in a global Phase 3 clinical trial called "BFORE," which is designed to assess the effectiveness and safety of BOSULIF(R) (bosutinib) as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML).
read article 



Venom Gets Good Buzz as Potential Cancer-fighter (Video)

(American Chemical Society) Aug 11, 2014 - Bee, snake or scorpion venom could form the basis of a new generation of cancer-fighting drugs, scientists will report.
read press release 



Shingles Vaccine Remains Effective After Chemotherapy

(Kaiser Permanente) Aug 6, 2014 - The herpes zoster vaccine continues to be effective in protecting older adults against shingles, even after they undergo chemotherapy, according to a Kaiser Permanente study published today in the journal Clinical Infectious Diseases.
read press release 



Psoriasis Ups Risk of Cancer, Serious Infection

(MedPage Today) Aug 8, 2014 - Rates of malignancy among patients with psoriasis outpaced national averages, irrespective of therapy in most cases, according to a study reported here.
read article (free registration required) 



New Melanomas Likely to Recur at Same Rate

(MedPage Today) Aug 9, 2014 - A diagnosis of in situ or invasive melanoma conferred a similar long-term risk of invasive melanoma recurrence, a 40-year retrospective review showed.
read article (free registration required) 



Merrimack Pharmaceuticals Announces Initiation of HERMIONE, a Randomized Trial of MM-302 in Patients With Advanced HER2-Positive Breast Cancer to Support Application for Accelerated Approval

(Yahoo! Finance) Aug 11, 2014 - Trial is recruiting patients previously treated with ado-trastuzumab emtansine (T-DM1) and pertuzumab.
read article 



Postmenopausal Breast Cancer Risk Decreases Rapidly After Starting Regular Physical Activity

(AACR) Aug 11, 2014 - Postmenopausal women who in the past four years had undertaken regular physical activity equivalent to at least four hours of walking per week had a lower risk for invasive breast cancer compared with women who exercised less during those four years, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
read press release 



FDA Approves VELCADE® (bortezomib) Retreatment in Patients with Multiple Myeloma

(MarketWatch) Aug 10, 2014 - Millennium: The Takeda Oncology Company with its parent company, Takeda Pharmaceutical Company Limited, today announced that the U.S. Food and Drug Administration (FDA) has approved VELCADE® (bortezomib) for the retreatment of adult patients with multiple myeloma (MM) who had previously responded to VELCADE therapy and relapsed at least six months following completion of prior VELCADE treatment.
read article